Non-Current Assets
Equity securities
Neurocrine Biosciences Equity securities increased by 20.9% to $146.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.1%, from $94.20M to $146.10M. Over 4 years (FY 2021 to FY 2025), Equity securities shows an upward trend with a 17.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ4 2021
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase reflects positive market performance of the underlying investments or additional capital deployment into equities.
Detailed definition
This represents the fair market value of the company's investment portfolio consisting of equity securities in other ent...
Peer comparison
Standard for companies with large corporate venture arms or significant treasury investment portfolios.
Metric ID:
ins_equity_securitiesHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $63.70M | $91.30M | $83.80M | $94.90M | $102.10M | $135.70M | $173.00M | $132.80M | $161.90M | $163.50M | $143.60M | $126.70M | $124.80M | $94.20M | $87.50M | $118.10M | $120.80M | $146.10M |
| QoQ Change | — | +43.3% | -8.2% | +13.2% | +7.6% | +32.9% | +27.5% | -23.2% | +21.9% | +1.0% | -12.2% | -11.8% | -1.5% | -24.5% | -7.1% | +35.0% | +2.3% | +20.9% |
| YoY Change | — | — | — | — | +60.3% | +48.6% | +106.4% | +39.9% | +58.6% | +20.5% | -17.0% | -4.6% | -22.9% | -42.4% | -39.1% | -6.8% | -3.2% | +55.1% |
Range$63.70M – $173.00M
CAGR+21.6%
Avg YoY Growth+18.1%
Median YoY Growth+8.6%
Current Streak3 quarters growth
Equity securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's equity securities?
- Neurocrine Biosciences (NBIX) reported equity securities of $146.10M in Q1 2026.
- How has Neurocrine Biosciences's equity securities changed year-over-year?
- Neurocrine Biosciences's equity securities increased by 55.1% year-over-year, from $94.20M to $146.10M.
- What is the long-term trend for Neurocrine Biosciences's equity securities?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's equity securities has grown at a 17.3% compound annual growth rate (CAGR), from $63.70M to $120.80M.
- What does equity securities mean?
- The current market value of the company's stock investments in other businesses.